Literature DB >> 7497843

Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis.

U Broomé1, R Löfberg, K Lundqvist, B Veress.   

Abstract

PURPOSE: This study is designed to describe colonic histology in patients with primary sclerosing cholangitis (PSC) without clinical symptoms of inflammatory bowel disease (IBD) and to do a follow-up study of these patients to find the time span from first detection of histologic signs until development of clinical symptoms of IBD.
METHODS: In a cohort of 76 patients with PSC treated at Huddinge University Hospital, 11 patients did not have any clinical symptoms of IBD at the time of PSC diagnosis. Nine of these patients underwent diagnostic colonoscopy with multiple biopsies.
RESULTS: In the group of nine PSC patients, without clinical signs of IBD undergoing colonoscopy, histologic signs of IBD were found in seven patients (6 ulcerative colitis and 1 Crohn's disease). Among them one had dysplasia, and another had epithelial changes probably positive for dysplasia. Two other patients had histologic signs of inflammation, however, not fully compatible with IBD. Three of 11 patients developed clinical symptoms of IBD after one, three, and seven years of follow-up since diagnostic colonoscopy.
CONCLUSIONS: In patients with PSC, histologic signs of IBD, including premalignant changes, may precede development of clinical symptoms of IBD by as much as seven years. This indicates that IBD onset may have a substantial subclinical phase of IBD far longer than previously appreciated. This finding may be of clinical importance because underestimation of disease duration may delay inclusion of PSC patients with extensive colitis in colonoscopic surveillance programs. The subclinical phase may also allow the studies of early pathogenesis in vivo.

Entities:  

Mesh:

Year:  1995        PMID: 7497843     DOI: 10.1007/bf02049156

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  17 in total

Review 1.  Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

Authors:  R T Prall; K D Lindor; R H Wiesner; N F LaRusso
Journal:  Curr Gastroenterol Rep       Date:  2000-04

Review 2.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

3.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

4.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  E V Loftus; G C Harewood; C G Loftus; W J Tremaine; W S Harmsen; A R Zinsmeister; D A Jewell; W J Sandborn
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 5.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 6.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 7.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

8.  Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases.

Authors:  T H J Florin; N Pandeya; G L Radford-Smith
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 9.  Colorectal cancer and dysplasia in inflammatory bowel disease.

Authors:  Timothy L Zisman; David T Rubin
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

10.  Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.

Authors:  Aliya F Gulamhusein; John E Eaton; James H Tabibian; Elizabeth J Atkinson; Brian D Juran; Konstantinos N Lazaridis
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.